PACB
Pacific Biosciences·NASDAQ
--
--(--)
--
--(--)
4.99 / 10
Netural
Analyst coverage is singular and bearish – 100% Sell rating from Barclays. Conversely, fund‑flow score is 8.13/10 (excellent), with strong inflows from large, extra‑large and block investors, though small and medium flows are negative. Strong liquidity contrasts with pessimistic analyst view.
Fund Flow Rating
Analyst RatingSell
Wall Street Opinions
Sell
Strong Buy
0%
Buy
0%
Hold
0%
Sell
100%
Strong Sell
0%
Date2026-03-06
InstitutionBarclays
Times predicted3
Historical Win Rate33.3%
What is the analyst consensus for PACB?
- PACB holds a Bearish analyst rating, with 100% of experts assigning a Sell grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.99/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
